HomeAI · summaries
Storia in 2 fonti
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro | Fortune
Eli Lilly reported stellar third-quarter earnings yesterday and raised this year’s revenue estimates from $60 billion–$62 billion to $63 billion–$63.5 billion.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
- ·
fortune.com
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and…
Eli Lilly reported stellar third-quarter earnings yesterday and raised this year’s revenue estimates from $60 billion–$62 billion to $63 billion–$63.5 billion.